To the Editor Fokkink and colleagues1 reported that hypoalbuminemia was associated with a severe clinical course and poor outcomes among patients with Guillain-Barré syndrome (GBS) who received intravenous immunoglobulin treatment. They proposed that the serum albumin could be a potential biomarker to monitor the treatment responses to intravenous immunoglobulin among patients with GBS.1 However, we have several concerns about the study.
Wang Y, Zhang H. Could Albumin Be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome? JAMA Neurol. 2017;74(7):871–872. doi:10.1001/jamaneurol.2017.0563
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.